[go: up one dir, main page]

AR134040A1 - Moduladores de mrgprx2 y métodos de tratamiento relacionados - Google Patents

Moduladores de mrgprx2 y métodos de tratamiento relacionados

Info

Publication number
AR134040A1
AR134040A1 ARP240102699A ARP240102699A AR134040A1 AR 134040 A1 AR134040 A1 AR 134040A1 AR P240102699 A ARP240102699 A AR P240102699A AR P240102699 A ARP240102699 A AR P240102699A AR 134040 A1 AR134040 A1 AR 134040A1
Authority
AR
Argentina
Prior art keywords
mrgprx2
modulators
treatment methods
compounds
related treatment
Prior art date
Application number
ARP240102699A
Other languages
English (en)
Inventor
Marion Lanier
Brandon Selfridge
Liming Huang
Adam Yeager
Marcus Boehm
Esther Martinborough
Original Assignee
Escient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escient Pharmaceuticals Inc filed Critical Escient Pharmaceuticals Inc
Publication of AR134040A1 publication Critical patent/AR134040A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente se divulgan compuestos con la estructura de la fórmula (1) o una sal, solvato, hidrato, isómero, tautómero, racemato o isótopo aceptable desde el punto de vista farmacéutico de este, en donde L¹, L², R¹, R², R³, R⁴ y m son como se definen en la presente. También se proporcionan composiciones farmacéuticas que los comprenden, procesos para prepararlos y sus usos para tratar o prevenir enfermedades, trastornos y afecciones. Los compuestos son moduladores de MRGPRX2 o del ortólogo de MRGPRX2, y son útiles en el tratamiento de enfermedades, trastornos y afecciones relacionados con la actividad de MRGPRX2 o del ortólogo de MRGPRX2.
ARP240102699A 2023-10-06 2024-10-04 Moduladores de mrgprx2 y métodos de tratamiento relacionados AR134040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363588638P 2023-10-06 2023-10-06

Publications (1)

Publication Number Publication Date
AR134040A1 true AR134040A1 (es) 2025-11-26

Family

ID=93258924

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240102699A AR134040A1 (es) 2023-10-06 2024-10-04 Moduladores de mrgprx2 y métodos de tratamiento relacionados

Country Status (4)

Country Link
US (1) US20250170141A1 (es)
AR (1) AR134040A1 (es)
TW (1) TW202517273A (es)
WO (1) WO2025076455A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025222040A1 (en) * 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7574215B2 (ja) * 2019-04-29 2024-10-28 ソレント セラピューティクス，エルエルシー ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体

Also Published As

Publication number Publication date
TW202517273A (zh) 2025-05-01
WO2025076455A1 (en) 2025-04-10
US20250170141A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
AR119731A1 (es) Inhibidores del inflamasoma nlrp3
UY39786A (es) Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades
AR116604A1 (es) Inhibidores de kras g12c
AR130727A1 (es) Compuestos tricíclicos y sus usos
PE20230238A1 (es) Inhibidores de kras g12c
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
AR113908A1 (es) Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
AR109437A1 (es) Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
MX2021015499A (es) Derivados de 2h-indazol y su uso en el tratamiento de enfermedades.
ECSP22083772A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
AR128622A1 (es) Inhibidores de la cinasa mek
AR126077A1 (es) Compuestos de pirrolil-sulfonamida
AR115906A1 (es) Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas
AR134040A1 (es) Moduladores de mrgprx2 y métodos de tratamiento relacionados
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
MX2023001725A (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos.
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
DOP2019000299A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias